The European Medicine Agency has begun reviewing a batch of new EU marketing authorization applications (MAAs) including two from Novartis, one of which covers the company’s potential blockbuster cardiovascular treatment, inclisiran.
Novartis’s other application that the EMA has newly added to its list of MAAs under review for pan-EU approval is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?